Clinical trial
Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For…
NCT00396383 · Genzyme, a Sanofi Company, Industry · Terminated
Key facts
| NCT number | NCT00396383 |
|---|---|
| Title | Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation |
| Official title | Treatment With AMD3100 in Multiple Myeloma Patients to Mobilize Peripheral Blood Progenitor Cells For Collection and for Transplantation |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Collaborators | AnorMED Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | plerixafor |
| Enrollment | 9 |
| Start date | Nov 1, 2004 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Nov 6, 2006 |
| Last update posted | Mar 13, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: